{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:39:57Z","timestamp":1790689197690,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#81872380"],"award-info":[{"award-number":["#81872380"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#81970864"],"award-info":[{"award-number":["#81970864"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["cstc2018jscx-mszdX0039"],"award-info":[{"award-number":["cstc2018jscx-mszdX0039"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005230","name":"Natural Science Foundation of Chongqing","doi-asserted-by":"publisher","award":["cstc2015jcyjBX0047"],"award-info":[{"award-number":["cstc2015jcyjBX0047"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Chongqing Health and Family Planning Commission Research Project","award":["2015HBRC004"],"award-info":[{"award-number":["2015HBRC004"]}]},{"name":"Chongqing Middle and Youth Medical High-end Talent Studio Project","award":["Yu Wei (2018) No. 2"],"award-info":[{"award-number":["Yu Wei (2018) No. 2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nasopharyngeal carcinoma tends to present at an advanced stage because the primary anatomic site is located in a less visible area and its clinical symptoms are nonspecific. Prognosis of advanced nasopharyngeal carcinoma cases remains disappointing. SEPT9 is a methylation-based biomarker approved by the US Food and Drug Administration for colorectal cancer screening and diagnosis. Interestingly, downregulation of SEPT9, especially SEPT9_v2, mediated by promoter hypermethylation has been also detected in head and neck squamous cell carcinoma than in head and neck squamous epithelium, while other SEPT9 variants did not. These reasons above indicate a crucial role of SEPT9_v2 in cancer progression. Therefore, we address the methylation status of SEPT9_v2 in nasopharyngeal carcinoma and explore the role of SEPT9_v2 in nasopharyngeal carcinoma proliferation and cancer progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SEPT9_v2 expression was found to be downregulated via promoter methylation in nasopharyngeal carcinoma cell lines and tissues. Ectopic expression of SEPT9_v2 induced G0\/G1 cell cycle arrest and apoptosis, which exerted an inhibitory effect in cell proliferation and colony formation. Additionally, nasopharyngeal carcinoma cell migration and invasion were shown to be inhibited by SEPT9_v2. Furthermore, our data suggested that SEPT9_v2 inhibits proliferation and migration of nasopharyngeal carcinoma cells through inactivation of the Wnt\/\u03b2-catenin signaling pathway via miR92b-3p\/FZD10.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study delineates SEPT9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of the Wnt\/\u03b2-catenin signaling pathway via miR92b-3p\/FZD10 in nasopharyngeal carcinoma cells and, hence, SEPT9_v2 may be a promising therapeutic target and biomarker for nasopharyngeal carcinoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-020-00833-5","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T11:03:56Z","timestamp":1583406236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["SEPT9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of Wnt\/\u03b2-catenin signaling pathway via miR92b-3p\/FZD10 in nasopharyngeal carcinoma cells"],"prefix":"10.1186","volume":"12","author":[{"given":"Yu","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dishu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxiu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"issue":"10","key":"833_CR1","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1039\/C4CS00370E","volume":"44","author":"L Wu","year":"2015","unstructured":"Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963\u201397.","journal-title":"Chem Soc Rev."},{"issue":"2","key":"833_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","volume":"20","author":"M Berdasco","year":"2019","unstructured":"Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20(2):109\u201327.","journal-title":"Nat Rev Genet."},{"issue":"3","key":"833_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12253-010-9338-7","volume":"17","author":"K Toth","year":"2011","unstructured":"Toth K, Galamb O, Spisak S, Wichmann B, Sipos F, Valcz G, et al. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. Pathol Oncol Res. 2011;17(3):503\u20139.","journal-title":"Pathol Oncol Res."},{"key":"833_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/1741-7015-9-133","volume":"9","author":"JD Warren","year":"2011","unstructured":"Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 2011;9:133.","journal-title":"BMC Med."},{"issue":"12","key":"833_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115415","volume":"9","author":"K Toth","year":"2014","unstructured":"Toth K, Wasserkort R, Sipos F, Kalmar A, Wichmann B, Leiszter K, et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS One. 2014;9(12):e115415.","journal-title":"PLoS One."},{"issue":"2","key":"833_CR6","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40291-017-0259-y","volume":"21","author":"YN Lamb","year":"2017","unstructured":"Lamb YN, Dhillon S. Epi proColon\u00ae 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther. 2017;21(2):225\u201332.","journal-title":"Mol Diagn Ther."},{"issue":"17","key":"833_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3748\/wjg.v25.i17.2099","volume":"25","author":"X Yang","year":"2019","unstructured":"Yang X, Xu ZJ, Chen X, Zeng SS, Qian L, Wei J, et al. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. World J Gastroenterol. 2019;25(17):2099\u2013109.","journal-title":"World J Gastroenterol."},{"issue":"3","key":"833_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nrm3284","volume":"13","author":"S Mostowy","year":"2012","unstructured":"Mostowy S, Cossart P. Septins: the fourth component of the cytoskeleton. Nat Rev Mol Cell Biol. 2012;13(3):183\u201394.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"5","key":"833_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.cell.2015.10.029","volume":"163","author":"S Koch","year":"2015","unstructured":"Koch S, Acebron SP, Herbst J, Hatiboglu G, Niehrs C. Post-transcriptional Wnt signaling governs epididymal sperm maturation. Cell. 2015;163(5):1225\u201336.","journal-title":"Cell."},{"issue":"11","key":"833_CR10","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1073\/pnas.96.11.6428","volume":"96","author":"M Osaka","year":"1999","unstructured":"Osaka M, Rowley JD, Zeleznik-Le NJ. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci U S A. 1999;96(11):6428\u201333.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"833_CR11","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41419-019-1947-9","volume":"10","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Cao Y, Liu L, Zhao J, Zhang T, Xiao L, et al. SEPT9_i1 regulates human breast cancer cell motility through cytoskeletal and RhoA\/FAK signaling pathway regulation. Cell Death Dis. 2019;10(10):720.","journal-title":"Cell Death Dis."},{"issue":"4","key":"833_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1593\/tlo.10109","volume":"3","author":"L Stanbery","year":"2010","unstructured":"Stanbery L, D\u2019Silva NJ, Lee JS, Bradford CR, Carey TE, Prince ME, et al. High SEPT9_v1 expression is associated with poor clinical outcomes in head and neck squamous cell carcinoma. Transl Oncol. 2010;3(4):239\u201345.","journal-title":"Transl Oncol."},{"issue":"5","key":"833_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/1541-7786.MCR-09-0497","volume":"8","author":"S Amir","year":"2010","unstructured":"Amir S, Golan M, Mabjeesh NJ. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway. Mol Cancer Res. 2010;8(5):643\u201352.","journal-title":"Mol Cancer Res."},{"issue":"5","key":"833_CR14","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/ijc.21486","volume":"118","author":"M Scott","year":"2006","unstructured":"Scott M, McCluggage WG, Hillan KJ, Hall PA, Russell SE. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. Int J Cancer. 2006;118(5):1325\u20139.","journal-title":"Int J Cancer."},{"issue":"4","key":"833_CR15","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/bcr2924","volume":"13","author":"D Connolly","year":"2011","unstructured":"Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, et al. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. Breast Cancer Res. 2011;13(4):R76.","journal-title":"Breast Cancer Res."},{"issue":"4","key":"833_CR16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.3892\/or.2016.5004","volume":"36","author":"S Matsui","year":"2016","unstructured":"Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, et al. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients. Oncol Rep. 2016;36(4):2225\u201335.","journal-title":"Oncol Rep."},{"key":"833_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13148-017-0425-4","volume":"9","author":"L de Vos","year":"2017","unstructured":"de Vos L, Gevensleben H, Schrock A, Franzen A, Kristiansen G, Bootz F, et al. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clin Epigenetics. 2017;9:125.","journal-title":"Clin Epigenetics."},{"key":"833_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/1471-2407-13-398","volume":"13","author":"R Wasserkort","year":"2013","unstructured":"Wasserkort R, Kalmar A, Valcz G, Spisak S, Krispin M, Toth K, et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer. 2013;13:398.","journal-title":"BMC Cancer."},{"issue":"6","key":"833_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin."},{"issue":"12","key":"833_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4161\/cbt.26170","volume":"14","author":"X Liu","year":"2013","unstructured":"Liu X, Luo HN, Tian WD, Lu J, Li G, Wang L, et al. Diagnostic and prognostic value of plasma microRNA deregulation in nasopharyngeal carcinoma. Cancer Biol Ther. 2013;14(12):1133\u201342.","journal-title":"Cancer Biol Ther."},{"issue":"10192","key":"833_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64\u201380.","journal-title":"Lancet."},{"issue":"29","key":"833_CR22","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1200\/JCO.2015.60.7846","volume":"33","author":"JP Bruce","year":"2015","unstructured":"Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. 2015;33(29):3346\u201355.","journal-title":"J Clin Oncol."},{"key":"833_CR23","unstructured":"MethHC Database, Copyright \u00a9 ISBLab 2014. http:\/\/MethHC.mbc.nctu.edu.tw. Accessed 17 April 2019."},{"key":"833_CR24","unstructured":"Kyoto Encyclopedia of Genes and Genomes, Copyright 1995-2019. http:\/\/www.kegg.jp. ."},{"issue":"1","key":"833_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-018-0045-7","volume":"20","author":"LFR Gebert","year":"2019","unstructured":"Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2019;20(1):21\u201337.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"833_CR26","unstructured":"Targetscan database, 2006-18 Whitehead Institute for Biomedical Research. http:\/\/www.targetscan.org\/. Accessed 15 May 2019."},{"issue":"3","key":"833_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/path.1789","volume":"206","author":"PA Hall","year":"2005","unstructured":"Hall PA, Jung K, Hillan KJ, Russell SE. Expression profiling the human septin gene family. J Pathol. 2005;206(3):269\u201378.","journal-title":"J Pathol."},{"issue":"2","key":"833_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1515\/hsz-2013-0247","volume":"395","author":"D Connolly","year":"2014","unstructured":"Connolly D, Hoang HG, Adler E, Tazearslan C, Simmons N, Bernard VV, et al. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue. Biol Chem. 2014;395(2):157\u201367.","journal-title":"Biol Chem."},{"key":"833_CR29","doi-asserted-by":"publisher","first-page":"44976","DOI":"10.1038\/srep44976","volume":"7","author":"P Verdier-Pinard","year":"2017","unstructured":"Verdier-Pinard P, Salaun D, Bouguenina H, Shimada S, Pophillat M, Audebert S, et al. Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments. Sci Rep. 2017;7:44976.","journal-title":"Sci Rep."},{"issue":"5","key":"833_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrc2389","volume":"8","author":"A Klaus","year":"2008","unstructured":"Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387\u201398.","journal-title":"Nat Rev Cancer."},{"key":"833_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/1476-4598-13-257","volume":"13","author":"Z Guan","year":"2014","unstructured":"Guan Z, Zhang J, Wang J, Wang H, Zheng F, Peng J, et al. SOX1 down-regulates beta-catenin and reverses malignant phenotype in nasopharyngeal carcinoma. Mol Cancer. 2014;13:257.","journal-title":"Mol Cancer."},{"issue":"1","key":"833_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-019-1023-4","volume":"38","author":"TS Liang","year":"2019","unstructured":"Liang TS, Zheng YJ, Wang J, Zhao JY, Yang DK, Liu ZS. MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt\/beta-catenin signaling pathway by down-regulating LHX2. J Exp Clin Cancer Res. 2019;38(1):97.","journal-title":"J Exp Clin Cancer Res."},{"issue":"1","key":"833_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-016-0384-1","volume":"35","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wen X, Ren XY, Li YQ, Tang XR, Wang YQ, et al. YPEL3 suppresses epithelial-mesenchymal transition and metastasis of nasopharyngeal carcinoma cells through the Wnt\/beta-catenin signaling pathway. J Exp Clin Cancer Res. 2016;35(1):109.","journal-title":"J Exp Clin Cancer Res."},{"issue":"11","key":"833_CR34","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/0008-5472.CAN-18-3592","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, et al. N(6)-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Res. 2019;79(11):2812\u201320.","journal-title":"Cancer Res."},{"issue":"7","key":"833_CR35","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1111\/cas.13636","volume":"109","author":"HK Li","year":"2018","unstructured":"Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagatsu K, et al. \u03b1-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018;109(7):2302\u20139.","journal-title":"Cancer Sci."},{"issue":"3","key":"833_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1349-7006.2008.01052.x","volume":"100","author":"S Nagayama","year":"2009","unstructured":"Nagayama S, Yamada E, Kohno Y, Aoyama T, Fukukawa C, Kubo H, et al. Inverse correlation of the up-regulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci. 2009;100(3):405\u201312.","journal-title":"Cancer Sci."},{"issue":"11","key":"833_CR37","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1158\/0008-5472.CAN-05-0120","volume":"65","author":"A Togashi","year":"2005","unstructured":"Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, et al. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma and potential target for molecular therapy. Cancer Res. 2005;65(11):4817\u201326.","journal-title":"Cancer Res."},{"issue":"1","key":"833_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.18632\/oncotarget.23159","volume":"9","author":"MP Scavo","year":"2018","unstructured":"Scavo MP, Fucci L, Caldarola L, Mangia A, Azzariti A, Simone G, et al. Frizzled-10 and cancer progression: is it a new prognostic marker? Oncotarget. 2018;9(1):824\u201330.","journal-title":"Oncotarget."},{"issue":"8","key":"833_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/cells8080777","volume":"8","author":"Scavo","year":"2019","unstructured":"Scavo MP, Depalo N, Rizzi F, Ingrosso C, Fanizza E, Chieti A, et al. FZD10 carried by exosomes sustains cancer cell proliferation. Cells. 2019;8(8).","journal-title":"Cells"},{"issue":"1-2","key":"833_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s11010-013-1882-5","volume":"387","author":"L Lei","year":"2014","unstructured":"Lei L, Huang Y, Gong W. Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2014;387(1-2):171\u20136.","journal-title":"Mol Cell Biochem."},{"issue":"3","key":"833_CR41","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3892\/or.2016.4940","volume":"36","author":"J Huang","year":"2016","unstructured":"Huang J, Wang B, Hui K, Zeng J, Fan J, Wang X, et al. miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. Oncol Rep. 2016;36(3):1693\u2013701.","journal-title":"Oncol Rep."},{"issue":"6","key":"833_CR42","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.3892\/or.2015.4323","volume":"34","author":"Z Liu","year":"2015","unstructured":"Liu Z, Diep C, Mao T, Huang L, Merrill R, Zhang Z, et al. MicroRNA-92b promotes tumor growth and activation of NF-kappaB signaling via regulation of NLK in oral squamous cell carcinoma. Oncol Rep. 2015;34(6):2961\u20138.","journal-title":"Oncol Rep."},{"issue":"1","key":"833_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-017-0723-7","volume":"16","author":"M Long","year":"2017","unstructured":"Long M, Zhan M, Xu S, Yang R, Chen W, Zhang S, et al. miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Mol Cancer. 2017;16(1):167.","journal-title":"Mol Cancer"},{"issue":"53","key":"833_CR44","doi-asserted-by":"publisher","first-page":"91603","DOI":"10.18632\/oncotarget.21342","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao C, Zhao F, Feng H, Xu S, Qin G. MicroRNA-92b inhibits epithelial-mesenchymal transition-induced migration and invasion by targeting Smad3 in nasopharyngeal cancer. Oncotarget. 2017;8(53):91603\u201313.","journal-title":"Oncotarget."},{"key":"833_CR45","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1038\/ncomms3532","volume":"4","author":"N Ageta-Ishihara","year":"2013","unstructured":"Ageta-Ishihara N, Miyata T, Ohshima C, Watanabe M, Sato Y, Hamamura Y, et al. Septins promote dendrite and axon development by negatively regulating microtubule stability via HDAC6-mediated deacetylation. Nat Commun. 2013;4:2532.","journal-title":"Nat Commun."},{"issue":"23","key":"833_CR46","doi-asserted-by":"publisher","first-page":"9524","DOI":"10.1073\/pnas.86.23.9524","volume":"86","author":"R Glaser","year":"1989","unstructured":"Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A. 1989;86(23):9524\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"833_CR47","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/jcb.25135","volume":"116","author":"T Chen","year":"2015","unstructured":"Chen T, Long B, Ren G, Xiang T, Li L, Wang Z, et al. Protocadherin20 acts as a tumor suppressor gene: epigenetic inactivation in nasopharyngeal carcinoma. J Cell Biochem. 2015;116(8):1766\u201375.","journal-title":"J Cell Biochem."},{"issue":"6","key":"833_CR48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/CEJ.0b013e328350b097","volume":"21","author":"D He","year":"2012","unstructured":"He D, Zeng Q, Ren G, Xiang T, Qian Y, Hu Q, et al. Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur J Cancer Prev. 2012;21(6):569\u201375.","journal-title":"Eur J Cancer Prev."},{"issue":"11","key":"833_CR49","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/1078-0432.CCR-09-3178","volume":"16","author":"L Li","year":"2010","unstructured":"Li L, Tao Q, Jin H, van Hasselt A, Poon FF, Wang X, et al. The tumor suppressor UCHL1 forms a complex with p53\/MDM2\/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res. 2010;16(11):2949\u201358.","journal-title":"Clin Cancer Res."}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-020-00833-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00833-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T14:40:47Z","timestamp":1666017647000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-00833-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["833"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-00833-5","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,5]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from each participant included in the study. This research was approved by the Institutional Ethics Committees of the First Affiliated Hospital of Chongqing Medical University (approval notice #20130306) and conformed to the tenets of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}